Anthoula Koliadi
Specialist physician at Department of Immunology, Genetics and Pathology; Research programme: Cancer Precision Medicine; Research group Ingrid Glimelius
- Mobile phone:
- +46 70 971 68 70
- E-mail:
- anthoula.koliadi@igp.uu.se
- Visiting address:
- Akademiska sjukhuset, ingång 100/101
751 85 Uppsala - Postal address:
- Akademiska sjukhuset, ingång 100/101
751 85 Uppsala
PhD student at Department of Immunology, Genetics and Pathology; Research programme: Cancer Immunotherapy; Research group Gustav Ullenhag
- Mobile phone:
- +46 70 971 68 70
- Visiting address:
- Akademiska sjukhuset, ingång 100/101
751 85 Uppsala - Postal address:
- Akademiska sjukhuset, ingång 100/101
751 85 Uppsala
More information is available to staff who log in.
Short presentation
Senior Consultant in Gynecological Oncology. In charge of the section of Gynecological Oncology at the Oncology Department, Akademiska Sjukhuset, Uppsala, Sweden
Keywords
- brachyterapi
- cervixcancer
- strålbehandling
- tumörbiologi
Publications
Recent publications
- Multiple immune-related adverse events secondary to checkpoint inhibitor therapy in patients with advanced cancer (2024)
- The role of dacarbazine and temozolomide therapy after treatment with immune checkpoint inhibitors in malignant melanoma patients (2024)
- Predicting immune-related adverse events using a simplified frailty score in cancer patients treated with checkpoint inhibitors (2023)
- Parity is associated with better prognosis in ovarian germ cell tumors, but not in other ovarian cancer subtypes (2022)
- Improved survival without increased toxicity with influenza vaccination in cancer patients treated with checkpoint inhibitors (2021)
All publications
Articles
- Multiple immune-related adverse events secondary to checkpoint inhibitor therapy in patients with advanced cancer (2024)
- The role of dacarbazine and temozolomide therapy after treatment with immune checkpoint inhibitors in malignant melanoma patients (2024)
- Predicting immune-related adverse events using a simplified frailty score in cancer patients treated with checkpoint inhibitors (2023)
- Parity is associated with better prognosis in ovarian germ cell tumors, but not in other ovarian cancer subtypes (2022)
- Improved survival without increased toxicity with influenza vaccination in cancer patients treated with checkpoint inhibitors (2021)
- Complete response with combined BRAF and MEK inhibition in BRAF mutated advanced low-grade serous ovarian carcinoma. (2020)
- High proliferation is associated with inferior outcome in male breast cancer patients (2013)
- Cyclin B is an immunohistochemical proliferation marker which can predict for breast cancer death in low-risk node negative breast cancer (2010)
- Cyclin B1 is a prognostic proliferation marker with a high reproducibility in a population-based lymph node negative breast cancer cohort (2010)
- Association between parity, histopathological tumor features and survival in high-grade serous ovarian cancer
Books
